Literature DB >> 8222319

Evaluation of in vivo immune complex formation and complement activation in patients receiving intravenous streptokinase.

J Freysdottir1, S Ormarsdottir, A Sigfusson.   

Abstract

The usefulness of several different methods for detecting immune complex formation and complement activation in the circulation were applied to samples from patients receiving intravenous Streptokinase therapy for myocardial infarction. Streptokinase is a foreign antigen and can cause immune reactions. We collected samples from 13 patients, before Streptokinase administration (baseline), at the end of infusion (1 h), 12 h later and on day 7. We measured IgG containing immune complexes (IgG-IC), free C3d and antibodies to Streptokinase by ELISA, and CR1, C3d and C4d on erythrocytes by flow cytometric assay. Antibodies to Streptokinase are common, as all but two of the patients had measurable antibody levels. During Streptokinase treatment there was a drop in antibody levels, most prominent in those patients who had high baseline levels. At the same time increased levels of free C3d and erythrocyte-bound C3d were observed. After 12 h free C3d was usually back to baseline level, but C3d on erythrocytes was still raised. These data indicate the formation of Streptokinase immune complexes in patients with high Streptokinase antibody levels, and show that these complexes are cleared rapidly from the circulation, leaving more persistent signs of complement activation. We conclude that free C3d is a good indicator of ongoing complement activation, whereas C3d on erythrocytes indicates that complement activation has recently taken place.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8222319      PMCID: PMC1534224          DOI: 10.1111/j.1365-2249.1993.tb03445.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  19 in total

1.  A flow cytometric assay for measuring complement receptor 1 (CR1) and the complement fragments C3d and C4d on erythrocytes.

Authors:  J Freysdottir; A Sigfusson
Journal:  J Immunol Methods       Date:  1991-08-28       Impact factor: 2.303

2.  Erythrocyte CR1 (C3b/C4b receptor) levels and disease activity in patients with SLE.

Authors:  B S Thomsen; H Nielsen; V Andersen
Journal:  Scand J Rheumatol       Date:  1987       Impact factor: 3.641

3.  Quantification of the C3d split products of human complement by a sensitive enzyme-linked immunosorbent assay.

Authors:  T E Mollnes
Journal:  Scand J Immunol       Date:  1985-06       Impact factor: 3.487

4.  Pharmacokinetics of streptokinase in patients based on amidolytic activator complex activity.

Authors:  D S Grierson; T D Bjornsson
Journal:  Clin Pharmacol Ther       Date:  1987-03       Impact factor: 6.875

5.  The relationship of anti-DNA antibody idiotypes and anti-cardiolipin antibodies to disease activity in systemic lupus erythematosus.

Authors:  D A Isenberg; C B Colaco; C Dudeney; A Todd-Pokropek; M L Snaith
Journal:  Medicine (Baltimore)       Date:  1986-01       Impact factor: 1.889

6.  Tetanus toxoid-anti-tetanus toxoid complexes: a potential model to study the complement transport system for immune complex in humans.

Authors:  J P Paccaud; G Steiger; A G Sjöholm; P J Spaeth; J A Schifferli
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

7.  Complement C3b receptors on erythrocytes in patients with juvenile rheumatoid arthritis.

Authors:  B S Thomsen; C Heilmann; S E Jacobsen; F K Pedersen; N Morling; B K Jakobsen; A Svejgaard; H Nielsen
Journal:  Arthritis Rheum       Date:  1987-09

8.  Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.

Authors:  G D Ross; W J Yount; M J Walport; J B Winfield; C J Parker; C R Fuller; R P Taylor; B L Myones; P J Lachmann
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

9.  The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus.

Authors:  R M Valentijn; H van Overhagen; H M Hazevoet; J Hermans; A Cats; M R Daha; L A van ES
Journal:  Arthritis Rheum       Date:  1985-08

10.  Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE).

Authors:  W Lloyd; P H Schur
Journal:  Medicine (Baltimore)       Date:  1981-05       Impact factor: 1.889

View more
  2 in total

1.  Low levels of plasma soluble complement receptor type 1 in patients receiving thrombolytic therapy for acute myocardial infarction.

Authors:  Ganesan Karthikeyan; Sivasankar Baalasubramanian; Sandeep Seth; Nibhriti Das
Journal:  J Thromb Thrombolysis       Date:  2006-11-28       Impact factor: 2.300

2.  Thrombolytic treatment and proteinuria.

Authors:  M Lynch; N V Hoffmann; C N Aroney
Journal:  Br Heart J       Date:  1995-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.